Charles Baker - Regeneron Pharmaceuticals Independent Director

REGN -- USA Stock  

Quarterly Earning Report: November 5, 2019  

  Director
Mr. Charles A. Baker, J.D., is no longer Independent Director of the Company effective June 8, 2018
Age: 84        
914 847 7000  http://www.regeneron.com
Baker retired as Chairman, President, and Chief Executive Officer of The Liposome Company, Inc., a biopharmaceutical company, a position he had held since December 1989. During his career, Mr. Baker served in a senior management capacity in various other pharmaceutical companies, including tenures as Group Vice President, Squibb Corporationrationrationration and President, Squibb International, and various senior executive positions at Abbott Laboratories and Pfizer Inc. From 1994 to 2013, Mr. Baker served as a member of the board of directors of Progenics Pharmaceuticals, Inc., a biopharmaceutical company. `

Charles Baker Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 11.57 % which means that it generated profit of $11.57 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.43 % meaning that it created $24.43 on every $100 dollars invested by stockholders.
The company currently holds 711.3 M in liabilities with Debt to Equity (D/E) ratio of 7.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Adriana KaraboutisPerrigo Company Plc
2017
Yuchun LeeVertex Pharmaceuticals Incorpor
2012
Gary CohenPerrigo Company Plc
2009
Omkar GoswamiDr Reddys Laboratories Ltd
2000
Anupam PuriDr Reddys Laboratories Ltd
2002
Larry CordellOrigin Agritech Limited
2012
James KangOrigin Agritech Limited
2010
Margaret McGlynnVertex Pharmaceuticals Incorpor
2011
David AltshulerVertex Pharmaceuticals Incorpor
2015
Lloyd CarneyVertex Pharmaceuticals Incorpor
2019
Jacqualyn FousePerrigo Company Plc
2012
David GreenwayVertex Pharmaceuticals Incorpor
2017
Herman MorrisPerrigo Company Plc
1999
Ashok GangulyDr Reddys Laboratories Ltd
2009
Kalpana MorpariaDr Reddys Laboratories Ltd
2007
Hans HaslerDr Reddys Laboratories Ltd
2016
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
2015
Leo PuriDr Reddys Laboratories Ltd
2018
Shikha SharmaDr Reddys Laboratories Ltd
2019
Shlomo YanaiPerrigo Company Plc
N/A
Robert ScullyZoetis
2013

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7549 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,549 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Did you try this?

Run Portfolio Center Now

   

Portfolio Center

All portfolio management and optimization tools to improve performance of your portfolios
All  Next Launch Module

Currently Active Assets on Macroaxis

DOX   
Purchased few shares of
few hours ago
Traded for 66.25
LN   
Purchased over 30 shares of
few hours ago
Traded for 36.33
SPNS   
Purchased over 100 shares of
few hours ago
Traded for 19.74
CBLK   
Purchased over 50 shares of
few hours ago
Traded for 26.0
TSEM   
Purchased few shares of
few hours ago
Traded for 21.83
Additionally take a look at Your Equity Center. Please also try Equity Search module to search for activelly-traded equities including funds and etfs from over 30 global markets.
Search macroaxis.com